Vifor Pharma (United States)

Vifor Pharma (United States)

CSL Vifor is a global specialty pharmaceuticals company in the treatment areas of iron deficiency, dialysis, nephrology & rare disease. It is headquartered in Switzerland and consists of CSL Vifor, Vifor Fresenius Medical Care Renal Pharma and Sanifit Therapeutics. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Vifor Pharma (United States), United States, covering academic research published from 2000 to 2024. Read More.


Open Access Percentage

51%


Total
Publications

184


Total Open
Publications

93


Total
Citations

4.7K


Open Access
Percentage

51%


Total
Publications

184


Total Open
Publications

93


Total
Citations

4.7K

Wikipedia

Website

download

Breakdown

17% 26% 7% 50%

Publisher Open

17%

Both

26%

Other Platform Open

7%

Closed

50%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

02468101214161820222426Total Publications
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Open

Closed

Publisher Open

48%OA Journal

OA Journal 48%

37

Hybrid 23%

18

No Guarantees 29%

22

Other Platform Open

Domain 79%

49

Institution 21%

13

Other Internet 15%

9

Preprint 5%

3

Public 3%

2

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
49
DOI
Other Internet
8
Le Centre pour la Communication Scientifique Directe - HAL - Diderot
Institution
4
Europe PMC
Domain
4
University of Michigan - Deep Blue
Institution
3
Research Square
Preprint
3
Unknown Repository
Other Internet
1
University of Milano-Bicocca - BOA
Institution
1
University of Lisbon - Repositório da Universidade de Lisboa
Institution
1
Universitat Autònoma de Barcelona - Dipòsit Digital de Documents de la UAB
Institution
1
1 / 2

Data updated 18 August 2025

Share

Share

Share